Abstract
The main demographic transition during the next decade will be a worldwide increase in older and elderly people, both in proportional and absolute terms. Although age itself is the main risk factor for morbidity and disability, additional cardiovascular risk may be brought about by inherent rises of blood pressure in these older age groups. This additional risk factor appears to be a suitable target for corrective measures. Recent therapeutic trials in mild or moderate hypertension all shared the common use of thiazides as one of the basic drugs of treatment. Subgroups of older hypertensives who were randomised to active treatment tended to fare better than those on placebo. This was mainly due to a reduction in cerebrovascular complications, but in the one trial where a potassium-sparing component was added to the thiazide, cardiac events were also reduced.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
